Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immun… Read more
Autobio Diagnostics Co Ltd (603658) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.88 Billion CNY
Based on the latest financial reports, Autobio Diagnostics Co Ltd (603658) has total liabilities worth CN¥2.88 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Autobio Diagnostics Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Autobio Diagnostics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Autobio Diagnostics Co Ltd Competitors by Total Liabilities
The table below lists competitors of Autobio Diagnostics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wanbangde Pharmaceutical Holding Group Co Ltd
SHE:002082
|
China | CN¥1.78 Billion |
|
Electricity Gnrtng NVtg
OTCGREY:EYUUF
|
USA | $124.04 Billion |
|
Qurient Co. Ltd
KQ:115180
|
Korea | ₩6.81 Billion |
|
PATTIES FOODS - Frankfurt Stock Exchang
F:PH4
|
Germany | €876.86 Million |
|
Nano Nuclear Energy Inc. Common Stock
NASDAQ:NNE
|
USA | $6.09 Million |
|
CT Real Estate Investment Trust
PINK:CTRRF
|
USA | $3.27 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Autobio Diagnostics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Autobio Diagnostics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Autobio Diagnostics Co Ltd (2011–2024)
The table below shows the annual total liabilities of Autobio Diagnostics Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.18 Billion | +10.23% |
| 2023-12-31 | CN¥2.89 Billion | +12.80% |
| 2022-12-31 | CN¥2.56 Billion | +39.94% |
| 2021-12-31 | CN¥1.83 Billion | +17.89% |
| 2020-12-31 | CN¥1.55 Billion | -4.34% |
| 2019-12-31 | CN¥1.62 Billion | +134.88% |
| 2018-12-31 | CN¥690.69 Million | +38.74% |
| 2017-12-31 | CN¥497.85 Million | +182.04% |
| 2016-12-31 | CN¥176.52 Million | -22.24% |
| 2015-12-31 | CN¥227.01 Million | +50.26% |
| 2014-12-31 | CN¥151.08 Million | +115.85% |
| 2013-12-31 | CN¥70.00 Million | +50.82% |
| 2012-12-31 | CN¥46.41 Million | +17.92% |
| 2011-12-31 | CN¥39.36 Million | -- |